CUE-101 continues to demonstrate safety, tolerability and meaningful clinical benefit in patients with HPV16+ R/M HNSCC.Clinical trial information: NCT03978689.Alexander Dimitrios ColevasStanford Cancer Center, Stanford, CAChristine H. ChungLee Moffitt Cancer Center and Research Institute, Tampa, FL...
Initiated Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s KEYTRUDA®, an anti-PD-1 biologic agent, as first-line therapy in patients with advanced HPV16+ head and neck cancer. Appointed renowned...
CUE-101, the first Immuno-STAT in clinical trials, is composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, a peptide epitope derived from the HPV16 E7 protein, and 4 molecules of attenuated human interleukin-2 (IL-2) designed to bind, expand, and activate HPV16-specific CD8...
Other novel Immuno-STATs, targeting local delivery of IL-2 for selective expansion and activation of additional tumor-antigen specific T cells, are in development.Clinical trial information: NCT03978689.Christine H. ChungMoffitt Cancer Center, Tampa, FL;A. Dimitrios Colevas...